Fibrosis

SAN DIEGO — Once-daily ALG-055009 achieved “significant and robust reductions” in liver fat at 12 weeks and was well-tolerated among noncirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to data.

SAN DIEGO — Patients with primary biliary cholangitis who were incomplete responders to obeticholic acid may still demonstrate improvement in inflammatory markers and fibrosis scores, according to research presented at The Liver Meeting.

SAN DIEGO — VK2809 demonstrated “robust reductions” in liver fat as early as 12 weeks in metabolic dysfunction-associated steatohepatitis, as well as MASH resolution and improvement in fibrosis by week 52, according to late-breaking data.

SAN DIEGO — Semaglutide was superior to placebo in metabolic dysfunction-associated steatohepatitis resolution and improvement in fibrosis at 72 weeks, with a safety profile consistent with previous studies, according to late-breaking data.

SAN DIEGO — Patients treated with once-monthly efimosfermin 300 mg achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis at 24 weeks, according to late-breaking data.

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, discusses data from the ongoing MAESTRO-NASH trial, which were presented at the ACG Annual Scientific Meeting.

Patients treated with denifanstat 50 mg vs. placebo achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis, according to study results in The Lancet Gastroenterology & Hepatology.

The FDA granted breakthrough designation to Sagimet Biosciences’ denifanstat for the treatment of patients with metabolic dysfunction-associated steatohepatitis and moderate to advanced fibrosis, according to a company press release.

Increased body surface area lowered the likelihood for nintedanib dose reduction/discontinuation among patients with fibrotic interstitial lung disease, according to results published in Respiratory Medicine.

Two years after COVID-19 hospitalization, 92% of patients continued to have either non-fibrotic-like or fibrotic-like lesions on CT scans, according to results published in The Lancet Regional Health — Americas.